Efficacy of Histone Deacetylase and Estrogen Receptor Inhibition in Breast Cancer Cells Due to Concerted down Regulation of Akt

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Thomas, Scott ^a   Thurn, K Ted ^a   Raha, Paromita ^a   Chen, Stephanie ^a   Munster, Pamela N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABEXINOSTAT; BIM PROTEIN; CYCLIN D1; CYTOCHROME C; DACTINOMYCIN; ESTROGEN RECEPTOR; HISTONE DEACETYLASE; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN KINASE B; SMALL INTERFERING RNA; TAMOXIFEN; TRICHOSTATIN A;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING;

APOPTOSIS; BENZOFURANS; BREAST NEOPLASMS; CELL LINE, TUMOR; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ESTROGEN; RNA, MESSENGER; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 84879946410     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068973     Document Type: Article

References (45)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics CA Cancer J Clin 60: 277-300. doi:10.3322/caac.20073. PubMed: 20610543.
2. Thomas S, Munster PN, (2009) Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. Cancer Lett 280: 184-191. doi:10.1016/j.canlet.2008.12.026. PubMed: 19185986.
3. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, et al. (2011) Invasive breast cancer. J Natl Compr Canc Netw JNCCN 9: 136-222.
4. Raha P, Thomas S, Munster PN, (2011) Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance. Epigenomics 3: 451-470. doi:10.2217/epi.11.72. PubMed: 22126205.
5. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, et al. (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366: 520-529. doi:10.1056/NEJMoa1109653. PubMed: 22149876.
6. Biçaku E, Marchion DC, Schmitt ML, Münster PN, (2008) Selective inhibition of histone deacetylase 2 silences progesterone receptor mediated signaling. Cancer Res 68: 1513-1519. doi:10.1158/0008-5472.CAN-07-2822. PubMed: 18316616.
7. Thomas S, Thurn KT, Biçaku E, Marchion DC, Münster PN, (2011) Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res Treat 130: 437-447. doi:10.1007/s10549-011-1364-y. PubMed: 21298336.
8. Hodges-Gallagher L, Valentine CD, Bader SE, Kushner PJ, (2006) Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells. Treat: Breast Cancer Res.
9. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, et al. (2011) A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 104: 1828-1835. doi:10.1038/bjc.2011.156. PubMed: 21559012.
10. Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, et al. (2011) Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res 17: 1147-1159. doi:10.1158/1078-0432.CCR-10-1869. PubMed: 21220480.
11. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, et al. (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68: 6084-6091. doi:10.1158/0008-5472.CAN-07-6854. PubMed: 18676830.
12. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, et al. (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448: 439-444. doi:10.1038/nature05933. PubMed: 17611497.
13. Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, et al. (1995) Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer J Int Cancer 64: 280-285. doi:10.1002/ijc.2910640412. PubMed: 7657393.
14. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, et al. (2001) AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159: 431-437. doi:10.1016/S0002-9440(10)61714-2. PubMed: 11485901.
15. Vivanco I, Sawyers CL, (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501. doi:10.1038/nrc839. PubMed: 12094235.
16. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM, (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101. doi:10.1126/science.1106148. PubMed: 15718470.
17. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, et al. (1998) Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 279: 710-714. doi:10.1126/science.279.5351.710. PubMed: 9445477.
18. Datta SR, Dudek H, Tao X, Masters S, Fu H, et al. (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241. doi:10.1016/S0092-8674(00)80405-5. PubMed: 9346240.
19. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, et al. (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868. doi:10.1016/S0092-8674(00)80595-4. PubMed: 10102273.
20. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA, (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789. doi:10.1038/378785a0. PubMed: 8524413.
21. Chen CS, Weng SC, Tseng PH, Lin HP, (2005) Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 280: 38879-38887. doi:10.1074/jbc.M505733200. PubMed: 16186112.
22. Alao JP, Stavropoulou AV, Lam EW, Coombes RC, Vigushin DM, (2006) Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. Mol Cancer 5: 8. doi:10.1186/1476-4598-5-8. PubMed: 16504004.
23. Alao JP, Stavropoulou AV, Lam EW, Coombes RC, (2006) Role of glycogen synthase kinase 3 beta (GSK3beta) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells. Mol Cancer 5: 40. doi:10.1186/1476-4598-5-40. PubMed: 17018141.
24. Bradley EW, Carpio LR, Westendorf JJ, (2013) Histone deacetylase 3 suppression increases PH domain and leucine-rich repeat phosphatase (Phlpp)1 expression in chondrocytes to suppress Akt signaling and matrix secretion. J Biol Chem 288: 9572-9582. doi:10.1074/jbc.M112.423723. PubMed: 23408427.
25. Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, et al. (2006) CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther 5: 1309-1317. doi:10.1158/1535-7163.MCT-05-0442. PubMed: 16731764.
26. Undevia SD, Janisch L, Schilsky RL, Loury D, Balasubramanian S, et al. (2008) Phase I study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the histone deacetylase inhibitor (HDACi) PCI-24781. J Clin Oncol 26 (suppl)(): abstr 14514.
27. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, et al. (2005) HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18: 601-607. doi:10.1016/j.molcel.2005.04.021. PubMed: 15916966.
28. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, et al. (2002) Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 277: 39858-39866. doi:10.1074/jbc.M206322200. PubMed: 12176997.
29. Lee RS, House CM, Cristiano BE, Hannan RD, Pearson RB, et al. (2011) Relative Expression Levels Rather Than Specific Activity Plays the Major Role in Determining In Vivo AKT Isoform Substrate Specificity. Enzyme Res, 2011(2011): 720985. PubMed: 21869924.
30. Yi X, Wei W, Wang SY, Du ZY, Xu YJ, et al. (2008) Histone deacetylase inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling. Biochem Pharmacol 75: 1697-1705. doi:10.1016/j.bcp.2007.10.035. PubMed: 18342836.
31. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, et al. (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280: 26729-26734. doi:10.1074/jbc.C500186200. PubMed: 15937340.
32. Fiskus W, Ren Y, Mohapatra A, Bali P, Mandawat A, et al. (2007) Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res 13: 4882-4890. doi:10.1158/1078-0432.CCR-06-3093. PubMed: 17699868.
33. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC, (2006) Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 66: 1277-1281. doi:10.1158/0008-5472.CAN-05-3632. PubMed: 16452179.
34. Wada T, Kikuchi J, Furukawa Y, (2012) Histone deacetylase 1 enhances microRNA processing via deacetylation of DGCR8. EMBO Rep 13: 142-149. doi:10.1038/embor.2011.247. PubMed: 22222205.
35. Lin RJ, Lin YC, Yu AL, (2010) miR-149* induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells. Mol Carcinog 49: 719-727. PubMed: 20623644.
36. Foley NH, Bray IM, Tivnan A, Bryan K, Murphy DM, et al. (2010) MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer 9: 83. doi:10.1186/1476-4598-9-83. PubMed: 20409325.
37. Li J, Chen Y, Zhao J, Kong F, Zhang Y, (2011) miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression. Cancer Lett 304: 52-59. doi:10.1016/j.canlet.2011.02.003. PubMed: 21354697.
38. Margueron R, Duong V, Castet A, Cavaillès V, (2004) Histone deacetylase inhibition and estrogen signalling in human breast cancer cells. Biochem Pharmacol 68: 1239-1246. doi:10.1016/j.bcp.2004.04.031. PubMed: 15313422.
39. Kawai H, Li H, Avraham S, Jiang S, Avraham HK, (2003) Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int J Cancer 107: 353-358. doi:10.1002/ijc.11403. PubMed: 14506733.
40. Alao JP, Lam EW, Ali S, Buluwela L, Bordogna W, et al. (2004) Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res 10: 8094-8104. doi:10.1158/1078-0432.CCR-04-1023. PubMed: 15585645.
41. Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, et al. (2006) CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther 5: 1309-1317. doi:10.1158/1535-7163.MCT-05-0442. PubMed: 16731764.
42. Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, et al. (2005) Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 65: 2422-2432. doi:10.1158/0008-5472.CAN-04-2440. PubMed: 15781658.
43. Ozaki K, Kosugi M, Baba N, Fujio K, Sakamoto T, et al. (2010) Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib. Biochem Biophys Res Commun 391: 1610-1615. doi:10.1016/j.bbrc.2009.12.086. PubMed: 20026060.
44. Erlich RB, Kherrouche Z, Rickwood D, Endo-Munoz L, Cameron S, et al. (2012) Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma. Br J Cancer 106: 107-115. doi:10.1038/bjc.2011.495. PubMed: 22116303.
45. Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, et al. (2012) Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study. J Clin Oncol Off J American Society Of Clinical Oncology, 30: 2718-24. PubMed: 22565002.